Lovelace’s support and the inclusion in a $20m NIH contract enable Exemplar to continue the development of a porcine animal model for Sickle Cell Disease research.
Eversana adopts Cryoport’s full suite of logistics services, in an alliance expected to ‘drive synergistic growth’ for both companies and answer regenerative medicine demands.
Sponsors to benefit from more accurate, shorter, and less costly trials through Shimmer Research and ClearSky Medical Diagnostics partnerships, says company executive.
Clinical trials are taking longer, drug development costing more, and the stakeholder group expanding – all compounding to create an "industrywide urgency to streamline how trials are run,” says Veeva VP.
Transforming statistical data into a surrogate endpoint can enable comprehension of trial results sooner than usual, but few make the cut after formal validation, says drug development expert and DIA panelist.
In which areas is artificial intelligence most mature? What are the challenges to widespread adoption? Tufts and DIA recently teamed up to explore these questions.
New this year to the discussion at DIA is the conversation around data ownership, as the industry continues to face a deluge of information from more sources than ever.
As regulators work to advance the modern clinical trial, the risk-averse clinical research industry is falling behind in the race to bring new therapies to patients, says an industry expert, echoing the former FDA commissioner’s calls for innovation.
University of Rochester Medical Center joined the global health research network aiming to ‘expand its access to advanced clinical trials’, TriNetX announced.
CRF Bracket is expanding its offering across the Asia-Pacific region with a new Tokyo office to help it better serve the area’s diverse and underserved patient population.
Biomarkers have the potential to improve drug development productivity by 34% over the next five years, during which period pre-screened patient pools and the application of predictive analytics also will help address the increasing complexity of clinical...
Acorn AI is designed to answer questions across all phases of drug development, making data “liquid” to help pharma make quick “go/no-go” decisions, accelerate clinical trials, and demonstrate value.
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.
Drug development – a dynamic and evolving process – is modernizing at an unprecedented rate, says industry expert, who stresses that change must continue to fully explore the opportunities.
The MI-based CRO MMS Holdings is among the team at the Health Analytics Collective, a research group hoping to reduce the need for new clinical trials by using readily available data – and an MIT-incubated programming language.
The All of Us research program is expanding its data collection abilities via Fitbit – a move that further demonstrates the industry’s increasing adoption of a BYOD approach, says Thread executive.
Strategikon Pharma releases new modules for its Clinical Maestro software suite – another step in the company’s journey to harmonize sponsor and CRO operations, with further updates slated for later this year, says CCO.
Awareness around the potential opportunities created by artificial intelligence has never been higher, but pharma’s biggest challenge in 2019 will be adopting and scaling the right technology to improve patient outcomes, says an industry executive.
The biopharma industry is on the precipice of making personalized medicine a reality with access to massive amounts of data, computing power, and artificial intelligence to run in silico clinical trials, says GNS Healthcare CEO.
The new “groundbreaking” model can translate the results of mouse experiments into the equivalent human condition, outperforming traditional methods of extrapolation by up to 50%, say researchers.
Blockchain provides real-time visibility into the entire clinical trial supply chain and has the potential to solve several of the industry’s biggest challenges.
LabCorp has launched Pixel by LabCorp, a consumer-initiated wellness test offering that allows for sample self-collection and access to online results.
Icon reported a record number of new business awards in Q3 and outlined its three-part patient recruitment strategy as well as global hiring – and acquiring – plans.
New guidances from the FDA update language and provide clarity for innovative approaches to the design and execution of clinical trials, say industry executives.
The FDA is calling on the digital health industry to innovate and proposing a new Center of Excellence for Digital Health – the timing of which is critical, as the industry is receiving more funding and opportunities than ever before, says industry exec.
Iqvia says its collaboration with Genomics England will help drugmakers and academics draw insights from clinical-genomic datasets – the ‘future of real-world research.’
TriNetX is releasing a series of new tools that will enable more people to conduct health research on their own, with access to rich datasets and analytics, says VP.
Cytel examines the gap between controlled experiment and real-world data at a time when the industry is collecting more data from more sources than ever before.
Taking inspiration from popular games such as Candy Crush and World of Warcraft, Data Cubed has developed a mHealth platform that promises to increase patient engagement in clinical research.
The top three myths of ‘going digital’ relate to the industry’s self-image, the perceived role of technology, and current market conditions – still, digital is not a fad and is here to stay, says industry expert.
Virtrial’s vision is to replace up to half of the standard clinical trial visits with virtual ones, using a hybrid approach incorporating telemedicine.
Robotics and automation will help improve the clunky and expensive clinical trial process, says Icon CEO – as the company continues to evaluate potential opportunities to improve efficiency.
CTTI’s latest recommendations will help researchers deploy mobile technologies in clinical trials and “pave the way for improving how we develop medicines,” says Pfizer exec.
The industry needs “to strike a balance” between science and feasible execution as increasingly complex clinical trial protocols are impeding efficiency and driving up costs, says industry expert.
The US FDA has released draft guidance documents on gene therapy programmes, which “should help sponsors avoid expending time and resources on unproductive drug development efforts,” says expert.
WCG and InformedDNA have established a new center for genetics and precision medicine in clinical trials – the increasing complexity of which, while potentially daunting, also creates the opportunity for transformational value, say industry experts.
Clinipace has launched a new branding for its collaborative approach to clinical trial management, which will “contribute to its goal of becoming the industry’s premier mid-sized CRO,” says CEO.
Real-world evidence, digital endpoints, and patient centricity are among the top trends in clinical trials – the benefits of which will be realized in part through advances in eClinical technology.
The drug development “finish line” is not regulatory approval, says Syenos Health chief scientific officer Judith Ng-Cashin, MD, who discusses bringing the payer and patient voice into the process.
Saama has launched a set of artificial intelligence (AI) capabilities designed to understand "typical life science domain questions" to better support clinical trial planning, feasibility, and conduct.
Novartis’ recently launched FocalView app will be used in a new study to remotely collect electronic device reported outcome measurements (eDROs) from 150,000 users.
